Intestinal Adaption and Others Treatment for individuals with short bowel syndrome is specially designed to quicken or strengthen the process of intestinal adaption and to supply sufficient nutritional support.
Intestinal adaption is the process by which the remaining or functional portion of the small bowel can adapt and increase its absorption to compensate for the missing or nonfunctioning segments; however, the amount of time intestinal adaption can take to occur is controversial. Initially, it was believed to occur only within 6 months of the loss of a portion of the small bowel. Now, many physicians believe it can occur as late as 2–3 years.
Researchers are investigating more ways to stimulate intestinal adaption further and to help the remaining small intestines to increase absorption and to function better.
Medications A variety of medications may be used to treat individuals with short bowel syndrome.
The therapeutic market size of SBS is accounted for by therapies directed towards the management of specific symptoms. These include proton pump inhibitors, choleretic agents, antidiarrheal agents, antisecretin agents, etc.
Apart from these, the off-label symptomatic therapies, the US FDA approved Zorbtive and pharmacological hormonal therapy, i.e., Teduglutide also contributes toward the market revenue for the disease. In May 2019, Takeda’s Gattex (teduglutide) got approval from the US FDA for the treatment of SBS in pediatric patients.
In some severe cases (e.g., cases in which individuals have lost all of their colon and ileum and some of the jejunum) or in individuals who do not respond to other medications, the somatostatin analog or octreotide, may be tried. Octreotide can significantly reduce diarrhea in some cases.
However, it can also inhibit intestinal adaption by preventing the release of important hormonal secretions. Drugs that prevent or reduce the release of stomach acid (e.g., histamine-2 receptor blockers and proton pump inhibitors) may also be used to treat individuals with short bowel syndrome.
Examples of such drugs include famotidine, ranitidine, omeprazole, and lansoprazole. Evidence suggests that excess acid secretions (hypersecretion) from the stomach can hinder intestinal adaption. These drugs are usually given early during the postoperative period when hypersecretion is greatest.
A small bowel transplant may be an option for some individuals with short bowel syndrome, especially those who have complications from TPN such as liver failure or who were unable to maintain proper nutrition with other therapies.
During a small bowel transplant, the small disease bowel is removed and replaced with one from a healthy donor. A variety of complications can occur with small bowel transplantation, including organ rejection, infections, and lymphoproliferative disease. In addition, the procedure is expensive and requires the lifelong use of immunosuppressive drugs to lessen the chance of rejection.
However, as surgical techniques and immunosuppressive agents improve in efficacy, survival has improved as well. Some individuals may receive a small bowel transplant along with a liver transplant (i.e., in cases with impending or frank liver failure) or other organs such as the kidney or pancreas.
Original Source:- Short bowel syndrome Market Research Report
Comments